Mammalian IDO is a heme-containing enzyme whose main activity in mammals is to degrade the essential amino acid tryp into L-kynurenine. Although the link between its enzymatic activity and the immune response is not straightforward, several lines of evidence suggest that this enzyme is involved in fighting infections and paradoxically, also in the establishment of the immune tolerance associated with fetus implantation and with the development of oncogenic processes. IDO is associated with the successful development of the fetus. It participates early in pregnancy to the efficient invasion of the uterine mucosa by the nascent trophoblast and remains active throughout the whole process, as illustrated by the decrease in systemic tryp from the second trimester of gestation and the return to normal values after delivery. The short-term activation of IDO in response to invading pathogens and emerging tumors participates in the elimination of these threats, whereas the sustained activation of IDO often results in a state of immune tolerance that may favor chronic infections and the uncontrolled proliferation of malignant cells. However, despite these potential deleterious effects of IDO, the enzyme is instrumental in maintaining the peripheral tolerance that is required to avoid autoimmune diseases. Below, we review the implication of IDO activation upon the physiological development of the fetus and the pathological development of tumors and discuss whether such an enzyme could be used as a therapeutic tool to decrease the rate of allograft rejections via its potent immunomodulatory properties.
Introduction
Fetuses, allografts, and tumors, although unrelated biological entities, are exposed to similar threats. All three are obliged to develop or maintain their integrity in an immunocompetent host and require the establishment of immune tolerance of the later to avoid their destruction.
Fetuses, which initiate their life as unicellular zygotes at conception and develop until term within the mother's body, are natural semiallogenic grafts, as one-half of their major histocompatibility antigen complex (MHC) is of paternal origin. Thus, the haplo-identical conceptus and in the artificial situation whereby the fetus is fostered by a third-party surrogate mother, the fully allogenic embryo develop to term only because of the establishment of immune tolerance by the mother.
Cancer, which is the uncontrolled proliferation of one abnormal clone, requires-especially for these cells expressing de novo antigenic, tumor-specific determinants-a state of immune tolerance from the host to avoid killing by the tumorspecific CTLs or NK cells.
Solid organ allografts, which most often exhibit MHC antigen mismatches with respect to the recipient, require immune tolerance to avoid rejection. Spontaneous tolerance does not generally occur in this situation, and chemical immunosuppressors have to be administered to the recipient to achieve graft survival.
STRUCTURE AND BIOCHEMICAL ACTIVITY OF IDO
IDO is a heme-containing peptidic enzyme found, to date, only in mammals and yeast [1] . In mammals, it is expressed essentially in lungs, cecum, colon, epididymis, and placenta [2] . IDO homologues, referred as proto-IDOs, have been found in various species. A paralog of IDO, named IDO2, which exhibits a higher homology with the proto-IDO family than with mammalian IDO, has been identified in humans and mice [3, 4] . IDO and IDO2 genes show a similar organization and are located, in humans and mice, adjacent to each other on chromosome 8, suggesting that mammal IDO results from the duplication of IDO2 [5] . As a result of the numerous molecular cofactors that have to be assembled with the core protein and with the catalytic heme to generate the activity of the enzyme, metabolically active IDO and IDO2 are found only in the cytosol. Both can catalyze the irreversible oxidation of the essential amino acid tryp in l-kynurenine but are inhibited by different chemicals. Moreover, IDO displays a high affinity and an efficient enzymatic activity toward tryp, whereas IDO2 exhibits a low affinity and a high Michaelis constant toward this molecule, suggesting that tryp may not be its natural substrate [3, 6 -8] .
The IDO family is ancient; that is, it emerged early on in the genome of provertebrates, before the establishment of the acquired immunity, approximately one-half of a billion years ago [9, 10] . Its coding sequence has been conserved since then, suggesting that the members of this family remain involved in higher vertebrate survival [11] . Ancestral IDOs, although showing a very similar exon/intron organization to the modern IDO found in mammals, essentially function as an O 2 carrier, like myoglobin, and do not exhibit tryp-degrading activity [12] . Mollusk proto-IDO exhibits a specific domain that can dock tryp (which may participate in O 2 fixation) but seems not to be able to degrade the amino acid [13] . The efficient degradation of tryp by the members of the IDO family is associated with the emergence of "modern" IDO in mammals and yeast [1] .
IMPLICATION IN THE IMMUNE RESPONSE
Initially, IDO gene expression was under the control of type I IFNs [14] and the chorionic gonadotropin [15] . During the course of evolution, the IDO gene has acquired control elements responding to IFN-␥ and TNF-␣ [16, 17] . IDO expression is now under the control of various proinflammatory cytokines synthesized by T lymphocytes and is involved in innate and acquired immune responses. It is expressed in many cell types, including mesenchymatous and monocytic cells [16, 18, 19] .
IDO substrate tryp is an essential amino acid. It is not synthesized by eukaryotes or by many prokaryote pathogens. Thus, tryp depletion provides to the host a way to eliminate pathogens by nutriment competition. IDO-induced tryp degradation is a key element against invading pathogens. The local degradation of tryp, close to or within the invaded cell (i.e., phagocytes or cells from epithelia or endothelia), very efficiently inhibits pathogen proliferation [20, 21] . In higher vertebrates, IDO-induced tryp depletion is crucial for the early containment of several pathogens, including Salmonella typhimurium, Listeria monocytogenes, and Toxoplasma gondii [17, [21] [22] [23] . As an example, myeloid DCs actively metabolizing tryp after TNF-␣-induced IDO activation are pivotal in the control of L. monocytogenes in humans [17] . This is consistent with the observation that therapies involving TNF-␣ antagonists, which may block IDO activation, often impair the DC antimicrobial effect, leading to overwhelming pathogen proliferation and the generation of suppurative granuloma [17] .
Tryp degradation products may also be toxic for some microbes and participate in their destruction, thus complementing tryp depletion [17, [21] [22] [23] .
Despite this beneficial effect at early times of inflammation, IDO-induced tryp depletion can inhibit various aspects of the immune response and cause chronic inflammation.
In the steady state, tryp is continously transported from the external milieu to the intracellular compartment, where it is complexed to tryptophanyl tRNA by the enzyme TTS [24] . Once complexed to tryptophanyl-tRNA, tryp is protected from IDO-driven degradation and is available for protein synthesis [25] [26] [27] .
Most cells remains metabolically active and respond to environmental cues only if the majority of tryptophanyl tRNA is loaded with tryp. If such a status is not reached, cells are driven toward apoptosis [28] . TTS expression is up-regulated by the same modulators as IDO in fibroblasts, keratinocytes, epithelial cells, and monocytes, enabling these cells to dock tryp efficiently on its tRNA, even when IDO is active, and tryp concentration is low [26] . Thus, cells expressing high levels of TTS (including IDO-positive cells actively decaying tryp) remain unaltered during transient external tryp depletion episodes associated with acute inflammation [29] .
T lymphocytes isolated from healthy individuals do not upregulate TTS as efficiently as other cells and are thus sensitive to IDO-induced tryp depletion [30] . Nevertheless, during a normal immune response involving IDO activation, inhibitory levels of tryp are reached after pathogens are eliminated [31] . Thus, IDO-induced T cell inhibition is viewed as the initial step to induce the reduction of the immune response.
Tryptophan catabolism may also be involved in the control of autoimmune diseases, as autoreactive T lymphocytes isolated from patients suffering from Graves' disease or from rheumatoid arthritis have lost their sensitivity toward IDO and tryp depletion, most obviously because they express TTS in much higher levels than T lymphocytes from healthy individuals [30, 32] .
In vitro, peripheral blood T lymphocytes purified from healthy individuals and activated in a medium depleted in tryp are locked in the late G1 phase and do not proliferate [33, 34] . Such inhibition can be avoided by complementing the medium with tryp or by adding IDO inhibitors if cultures contain cells expressing active IDO [26, 28, 33] . This specific situation identified IDO-expressing cells as a potent tool to control alloreactive T cells that induce, in many instances, unwanted side-effects in grafted patients. Currently, IDO-expressing cells from various origins, including mesenchymal stromal cells, are being tested for their ability to control allograft rejection or graft-versus-host disease [35, 36] .
Although tryp depletion is central to the immunomodulatory effect attributed to IDO, the compounds generated by the degradation of tryp, which are involved in various biological systems (for review, see ref. [37] ), may also be involved in immunoregulatory functions. As an example, kynurenic acid, which is metabolized directly from l-kynurenine, is involved in the early stages of monocyte and neutrophil adhesion to vascular endothelium [38] . IDO expression is restricted to specific tissues [2] , and its activation produces a local tryp depletion (the exception being the status of the pregnant women; see below). However, as l-kynurenine or kynurenine metabolites can diffuse in the bloodstream, IDO activation may induce a generalized control of the immune response via the effects of the soluble mediators produced by tryp metabolism [39] . Indeed, recent studies support this contention by showing that tryp depletion and l-kynurenine derivatives, when combined, induce a sustained control of the immune response [40 -42] .
Altogether, these observations show that the interaction between IDO and the acquired immune response is a delicate balance. The censoring of T lymphocytes by IDO, if occurring too early or too vigorously, may induce a premature arrest of the response that may impair pathogen clearance and favor the establishment of a chronic disease [43] .
Nevertheless, despite these potential deleterious effects of IDO-induced T cell inhibition, the enzyme is instrumental in maintaining peripheral tolerance and avoidance of autoimmune diseases, as is illustrated by the propensity of mice genetically knocked down for IDO to develop exacerbated collagen-induced arthritis [44] and by the resistance of autoreactive human T lymphocytes to IDO inhibition in some autoimmune diseases [30, 32] .
IDO AND PREGNANCY
Pregnancy is the guardian of mammalian (including homo sapiens) perenniality. During the entire process, the semiallogenic fetus is tolerated by the mother, protected by a very efficient process of immune tolerance. As mentioned earlier, such tolerance is so powerful that human surrogate mothers, bearing a fully allogenic fetus, do not experience a higher rate of fetus loss (13%) [45] compared with women undergoing haploidentical in vitro fecundation [46, 47] . Mother-to-fetus tolerance is not restricted to humans and has been well demonstrated in nature: natural interspecies "semixenogenic" pregnancies occur in mammals, leading to a viable, hybrid progeny-breeding a mare with a donkey or a cow with a yak are classical examples. Moreover, with the help of human intervention, fully xenogenic pregnancies can be achieved. The artificial implantation of a zebra embryo in a horse mare gives birth to a normal, viable zebra, further emphasizing the power of the immunological tolerance operative during pregnancy [48] .
Immune tolerance within the uterus is very efficient. If an allogenic somatic (nonfetal) tissue is implanted in the decidua basalis of a pregnant mouse, it will engraft and survive [49] . However, if the same tissue is implanted in the vicinity of the uterus but not in the organ, it will be rejected, demonstrating that tolerance is spatially restricted to the uterus [49] . Moreover, if embryonic tissue is implanted elsewhere in the body of a pregnant mouse other than in the uterus, it will be rejected, whereas embryos residing in this organ will develop normally [49] .
Altogether, these observations suggest that the uterus environment is pivotal in establishing immune tolerance and that such tolerance also holds true for nonfetal tissue implantation.
The nature of the molecules responsible for the establishment of immune tolerance during human pregnancy has been investigated intensively. IDO was found to be expressed in the placenta [50] . Its enzymatic signature can be identified after a short-term ex vivo culture of syncytiotrophoblast or villous explants, where it depletes tryp from the medium, generating conditioned supernatants that inhibit T lymphocyte proliferation in vitro [51, 52] .
These observations, as well as the evidence that maternal T cells specific for paternally inherited MHC antigens are transiently inhibited during pregnancy [53] , prompted investigators to assess the role of IDO in pregnant mice [54] .
Mice undergoing syngenic or semiallogenic pregnancies were injected with 1-MT early after conception, and the course of fetus survival was monitored. Syngenic fetuses were not affected by the inhibitor, whereas semiallogenic fetuses were systematically lost, indicating that IDO was required to block the recognition of the paternal MHC antigens by maternal T cells [54] . Subsequent experiments involving the mating of transgenic mice that were engineered to be genetically deficient in IDO were performed. Both syngenic and semiallogenic pregnancies were initiated in these IDO-deficient animals. IDO genetic inactivation did not affect the size of the litter compared with WT animals, thus suggesting that other mechanisms involved in the process of fetus tolerance, which are not identified in unmanipulated animals, can substitute IDO in IDOdefficient mice [55] .
In humans, the contribution of IDO in fetus tolerance remains controversial. Although supernatants from ex vivo cultures of human syncytiotrophoblast or villous explants are depleted in tryp [56] , the addition of 1-MT during such cultures does not fully recover their inhibitory potential upon T cell proliferation, indicating that tryp depletion is not the sole mechanism involved in T cell blockade. Indeed, various soluble factors, known to inhibit T cells, have been identified in these supernatants [56, 57] .
Recently, the determination of IDO expression and its biological activity in human fetal tissues have been carefully revisited [58] . This showed that during pregnancy IDO is expressed in the vascular endothelium of the decidua and of the villous chorion but not in the trophoblast, and its expression follows a gradient, reaching its highest concentrations at the feto-maternal interface. The enzyme is active, as demonstrated by the elevated ratio of l-kynurenine/tryp in the chorionic blood compared with the peripheral blood of nonpregnant adults. Whether in vivo tryp depletion is sufficient to mediate maternal T cell or NK cell inhibition or whether tryp metabolites are involved in the process has not been elucidated. An extended depletion of tryp within the feto-maternal interface integrality would certainly be deleterious to the fetus who requires the amino acid for survival [59] . Thus, a direct effect of tryp depletion seems conceivable only if effective when occurring in a specific, closed microenvironment, such as a cell-cell synapse, whereby deep tryp depletion can be achieved without leakage and subsequent deleterious effect on the fetus. By contrast, the synthesis of tryp catabolites may reach inhibitory levels upon immunocompetent maternal cells without inducing a complete depletion of tryp in the feto-maternal interface. Furthermore, it remains to be established whether IDO in this context induces immune tolerance essentially or whether, as recently suggested, it may also play a role via the production of l-kynurenine in keeping the vessels of the fetus dilated to ensure survival [58, 60] .
IDO is also involved in the initial invasion of the endometrial tissue by trophoblastic cells, as suggested by observations on human preeclampsia. Preeclampsia is a pathology that occurs during pregnancy, leading to maternal hypertension, proteinuria, and to growth retardation of the fetus. In some cases, it can evolve to overt eclampsia, with symptoms concerning the pregnant women that resemble those of epilepsy, which can lead to maternal and subsequently, fetus death. The disease is associated with a decreased invasion of the trophoblast into the uterine wall compared with normal pregnancies [61] . Moreover, term placentas from preeclamptic pregnancies are smaller and contain less functional IDO, as determined by a decreased ratio of l-kynurenine/tryp in this tissue compared with normal pregnancies [62] . Thus, IDO is associated with the efficient invasion of the uterine mucosa by the nascent trophoblast, which is a prerequisite for the occurrence of a normal pregnancy [63, 64] . IDO also seems to be involved in the later stages of pregnancy, as illustrated by the decrease of systemic tryp in pregnant women from the second trimester of gestation and the return to normal values after delivery [65] .
Altogether, these observations suggest that IDO, although certainly sharing its role with other molecular mediators, is a key element controlling pregnancy.
IDO AND CANCER: INHIBITING OR FAVORING TUMOR GROWTH?
Deciphering the biology of cancer and the response of the host against it is a difficult task, as most, if not all, of the observations available are gathered from individuals whereby the tumor proliferates, indicating that the anti-tumor immune response of the host has indeed failed. By definition, a successful anti-tumor response consists in the early identification of the tumor and its efficient destruction before it can escape actions of effectors and cause harm to the host. The activation of IDO in the vicinity of an emerging tumor could participate in its neutralization, as numerous cell lineages from which tumors are derived are sensitive to tryp depletion [66, 67] . One would expect, for instance, that malignancies of T cell origin could be controlled by IDO and eradicated via tryp depletion. Indeed, most of the tumoricidal activity of IFN-␥ may be attributed to the activation of IDO in peritumoral macrophages or in the tumor cell themselves [68] . However, many tumors acquire the ability to proliferate in an environment highly depleted in tryp and may even constitutively express metabolically active IDO [69 -71] . Such cells escape from the control of the peritumoral IDOϩ cells, as well as of cytotoxic T and NK cells, as these are inhibited by IDO.
A retrospective study of 40 patients suffering from a malignant melanoma showed that the presence, at diagnosis, of IDOϩ cells in the LN draining the tumor correlated with a poor clinical outcome compared with that of patients devoid of such cells, suggesting that these IDOϩ cells could be involved in the unresponsivness of NK and T cells [72] . Subsequent in vivo experiments were performed by inoculating mice with a mouse melanoma and harvesting various cellular subpopulations from the tumor draining LNs of these animals. A minute (0.3-0.5% of the total LN cellularity) population of IDOϩ plasmacytoid DCs, which was absent in other LNs of tumor-bearing animals, was identified in most animals and found to block tumor-specific T cell proliferation in vitro. Moreover, the adoptive transfer of these cells in a secondary host induced immunologic unresponsivness [72] , further suggesting that a very small number of IDOϩ cells recruited to the tumor draining LN were sufficient to allow tumor escape from the immune system [73, 74] .
Altogether, these observations may explain the relative failure of unmanipulated anti-tumor CD8 ϩ T cells, present in the circulation of tumor-bearing individuals, to fight established macroscopic tumors [75, 76] and question the ability of the acquired immune system to control tumors. This issue is indeed challenged further by the observation that colonial provertebrate organisms, which are naturally devoid of elements of the acquired immune system, are no more prone to cancers than higher vertebrates [77] and that Rag-1-deficient mice that are devoid of functional B and T lymphocytes and NK T cells but exhibit a functional innate immune system do not show a higher frequency of spontaneous tumors than fully immunocompetent mice [78, 79] .
Yet, this does not mean that tumor-specific CD8 ϩ T cells cannot eradicate tumors before the malignancy enters the "chronic phase", which is often associated with the establishment of an immunosuppressive environment.
In summary, IDO may exert two opposite effects upon the fate of tumor cells, as it does on pathogens. Early in tumor development, IDO may efficiently block the progression and eliminate a tryp-dependent tumor via tryp depletion. In this situation, the survival of the tumorigenic cells will be so short that they will remain hardly detectable, in the same way that minute pathogen invasion through a skin microlesion will occur unnoticed because pathogens will be controlled immediately by the early innate response. By contrast, if a tumor survives the initial IDO inhibition and requires the activation of the acquired immune response to be eradicated, it may access a "chronic state", which can favor, as a result of the presence of active IDO, the establishment of an inhibitory niche that will neutralize any potential anti-tumor response provided by the acquired immune system. Thus, once a tumor is established and actively growing, blocking IDO activity could be a good strategy to eradicate it. Along these lines, inhibitors of IDO, including natural molecules, are currently being investigated as adjuvants for various cancer therapies [80, 81] . Such an approach looks encouraging [82, 83] , although IDO suppression in this context is expected to increase inflammation, which may, in turn, favor tumor progression. Probably, the use of IDO inhibitors in cancer treatment may produce the same side-effects as those observed during anti-TNF-␣ therapies and will have to be graded with extreme care.
THERAPEUTIC EFFECTS IN SOLID ORGAN ALLOGRAFTING TOLERANCE
In contrast to the fetus and malignant tumors that are able to subvert the immune system and establish a state of immune tolerance, solid allografts require artificial immunosuppression of the host to avoid destruction.
Why is the haplo-identical fetus able to induce a state of tolerance that protects it from immunological threats, whereas the survival of a grafted haplo-identical kidney, exhibiting a similar MHC (mis)match with respect to the recipient, requires lifelong chemical immunosuppression? The uterus, as discussed above, certainly plays an important role in the establishment of tolerance, but this may not be the unique reason. Many tumors residing outside of the uterus and bearing de novo antigens, which could be targeted by tumor-specific cytotoxic T lymphocytes, fool the immune system and grow unaffected. Thus, something else is shared between tumors and fetus and is absent in grafted allogenic organs. Specific molecules that may be up-or down-modulated exclusively by the fetus and tumors may not be similarly modulated by the artificially implanted allograft. Fetus and tumors share a very similar early history of implantation, which is initiated at the single-cell stage in the absence of any vascularization. Then, the ectopic tissue slowly develops without inducing inflammation and may therefore present its various endogenous peptides via the MHC to the host immune system in a tolerogenic context. It is only after several weeks of progression, once these structures have reached a sufficient volume, that they will develop a vascular bead. At this time, one may assume that the fetus and tumors have established a local immune tolerance that will protect them from host-immunocompetent cells cruising in the neovasculature.
By contrast, allografts represent an enormous bulk of cells comprising a pre-existing vascular tree that is connected immediately and without delay to the systemic circulation of the host. As grafted organs are generally ischemic at the time of the chirurgical intervention, reperfusion induces the release of inflammatory mediators within the graft, which in turn, recruits inflammatory cells to the graft. Moreover, reperfusion may flush the APCs from the allogenic graft to the secondary lymphoid organs of the host, where they can further activate alloreactive T lymphocytes that have been primed by the inflammatory environment. Altogether, these events induce an intense immune response directed against the graft that will provoke its rejection. Such processes do not occur when the fetus and tumors nest in their tissue of choice as single cells and progressively grow in situ.
IDO represents a potent therapeutic tool to assist solid organ allografting, as its immunoregulatory potency is important, and by contrast, to cyclosporin A or corticosteroids, it seems not to be associated with nephrotoxicity, bone resorption, or weight gain. However, IDO is a multimeric intracytoplasmic enzyme that must be logged in a cell to process its substrate and cannot be administered to patients in the same way as a conventional drug. Nevertheless, targeting IDO to grafted organs may be possible by infusing the recipient with cells naturally expressing IDO or genetically modified to do so [84 -86] . Along these lines, mesenchymal stromal cells, which naturally express high levels of IDO after stimulation with IFN-␥, are foreseen as a potent adjuvant for allografting. Moreover, recent experiments have shown that cell-surface modification of the carbohydrate content of homing molecules allows targeting of infused cells to specific compartments in the host [87, 88] . Cell therapy will allow use of IDO as an efficient immunomodulator that may deliver its effect locally, thus limiting the potential side-effects of systemic immunosuppression.
CONCLUDING REMARKS
IDO is an enzyme involved in multiple biological processes. Initially functioning as an oxygen carrier in early provertebrates, it evolved into a powerful but ambivalent immune regulator in mammals. IDO is recognized as potent stimulator of the early immune response against pathogens and tumors. By contrast, IDO also comprises a "dark side" when interplaying with chronic responses of the acquired immune system. If censoring of T lymphocytes by IDO occurs too early or too vigorously, the inability to clear pathogens or tumor burden may ensue. However, despite these potential deleterious effects, IDO remains instrumental in the survival of mammals, including humans, as illustrated by its prominent role in fetus survival and in the avoidance of autoimmune diseases.
Complementary investigations are required to fully understand the importance of IDO in these processes. The relative importance of tryp depletion versus l-kynurenine derivative synthesis remains to be established, especially since the identification of the enzyme tryptophan hydroxylase-1, which degrades the amino acid via the serotonin pathways (thus without involving kynurenine derivatives) as a powerful inhibitor of the immune response [89] .
Moreover, identifying more precisely the molecular mechanisms inducing tolerance between the mother and the haploidentical fetus would certainly help design clinical strategies that would increase the success of solid organ allografting. AUTHORSHIP V.K. initiated the project and wrote the first draft, S.D. searched the literature in PubMed, and both authors contributed to the writing of the final version.
